Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Sales and Divestitures: 2016-2023

Historic Gains from Sales and Divestitures for Editas Medicine (EDIT) over the last 7 years, with Jun 2023 value amounting to $210,701.

  • Editas Medicine's Gains from Sales and Divestitures fell 9.46% to $210,701 in Q2 2023 from the same period last year, while for Jun 2023 it was $210,701, marking a year-over-year decrease of 9.46%. This contributed to the annual value of $286,642 for FY2022, which is 7.25% up from last year.
  • Per Editas Medicine's latest filing, its Gains from Sales and Divestitures stood at $210,701 for Q2 2023, which was up 44.11% from $146,209 recorded in Q1 2023.
  • In the past 5 years, Editas Medicine's Gains from Sales and Divestitures registered a high of $304,638 during Q4 2020, and its lowest value of $18,000 during Q1 2019.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $200,888 (2021), whereas its average is $195,707.
  • In the last 5 years, Editas Medicine's Gains from Sales and Divestitures crashed by 82.70% in 2019 and then spiked by 1,085.52% in 2020.
  • Editas Medicine's Gains from Sales and Divestitures (Quarterly) stood at $99,919 in 2019, then spiked by 204.88% to $304,638 in 2020, then fell by 12.27% to $267,268 in 2021, then grew by 7.25% to $286,642 in 2022, then fell by 9.46% to $210,701 in 2023.
  • Its Gains from Sales and Divestitures stands at $210,701 for Q2 2023, versus $146,209 for Q1 2023 and $286,642 for Q4 2022.